FDA to Require 50 Percent Efficacy for COVID-19 Vaccines

Vaccine experts divided on whether that level of protection is too low or too demanding.

amanda heidt
| 2 min read
covid-19, pandemic, SARS-CoV-2, coronavirus, vaccine, fauci, FDA, medicine, vaccine development

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK, MOUSSA81

The US Food and Drug Administration has released a set of guidelines outlining the approval process for future COVID-19 vaccines, stating that any product will need to prevent or decrease the severity of the disease by at least 50 percent.

The new guidelines were released during a June 30 briefing with the Senate Health, Education, Labor and Pensions Committee during which senators sought assurances from FDA Commissioner Stephen Hahn, National Institute of Allergy and Infectious Diseases Director Anthony Fauci, and other high-ranking health officials that the expedited speed of development wouldn’t compromise the integrity of the final product.

“I want the American people to hear me when I say we will use the science and data from those trials, and will ensure that our high levels of standards for safety and efficacy are met,” Hahn said during the briefing.

Currently, more than 145 vaccines are being ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • amanda heidt

    Amanda Heidt

    Amanda was an associate editor at The Scientist, where she oversaw the Scientist to Watch, Foundations, and Short Lit columns. When not editing, she produced original reporting for the magazine and website. Amanda has a master's in marine science from Moss Landing Marine Laboratories and a master's in science communication from UC Santa Cruz.
Share
A greyscale image of cells dividing.
March 2025, Issue 1

How Do Embryos Know How Fast to Develop

In mammals, intracellular clocks begin to tick within days of fertilization.

View this Issue
Discover the history, mechanics, and potential of PCR.

Become a PCR Pro

Integra Logo
Explore polypharmacology’s beneficial role in target-based drug discovery

Embracing Polypharmacology for Multipurpose Drug Targeting

Fortis Life Sciences
3D rendered cross section of influenza viruses, showing surface proteins on the outside and single stranded RNA inside the virus

Genetic Insights Break Infectious Pathogen Barriers

Thermo Fisher Logo
A photo of sample storage boxes in an ultra-low temperature freezer.

Navigating Cold Storage Solutions

PHCbi logo 

Products

The Scientist Placeholder Image

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

Stirling Ultracold

Meet the Upright ULT Built for Faster Recovery - Stirling VAULT100™

Stirling Ultracold logo
Chemidoc

ChemiDoc Go Imaging System ​

Bio-Rad
The Scientist Placeholder Image

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb